$16.25
3.17% yesterday
NYSE, May 20, 10:00 pm CET
ISIN
VGG111961055
Symbol
BHVN
Sector
Industry

Biohaven Pharmaceutical Holding Company Ltd. Target price 2025 - Analyst rating & recommendation

Biohaven Pharmaceutical Holding Company Ltd. Classifications & Recommendation:

Buy
94%
Hold
6%

Biohaven Pharmaceutical Holding Company Ltd. Price Target

Target Price $56.08
Price $16.25
Potential
Number of Estimates 15
15 Analysts have issued a price target Biohaven Pharmaceutical Holding Company Ltd. 2026 . The average Biohaven Pharmaceutical Holding Company Ltd. target price is $56.08. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 16 analysts: 15 Analysts recommend Biohaven Pharmaceutical Holding Company Ltd. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Biohaven Pharmaceutical Holding Company Ltd. stock has an average upside potential 2026 of . Most analysts recommend the Biohaven Pharmaceutical Holding Company Ltd. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share $ -9.28 -7.44
61.95% 19.83%
P/E negative
EV/Sales 112.28

16 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast for earnings per share. The average Biohaven Pharmaceutical Holding Company Ltd. EPS is

$-7.44
Unlock
. This is
20.60% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-5.88 37.25%
Unlock
, the lowest is
$-9.08 3.09%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-9.28 61.95%
2025
$-7.44 19.83%
Unlock
2026
$-6.22 16.40%
Unlock
2027
$-5.01 19.45%
Unlock
2028
$-2.98 40.52%
Unlock
2029
$-1.21 59.40%
Unlock

P/E ratio

Current -1.74 68.19%
2025
-2.18 25.29%
Unlock
2026
-2.61 19.72%
Unlock
2027
-3.24 24.14%
Unlock
2028
-5.45 68.21%
Unlock
2029
-13.46 146.97%
Unlock

Current Biohaven Pharmaceutical Holding Company Ltd. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
RBC Capital
Locked
Locked
Locked May 19 2025
RBC Capital
Locked
Locked
Locked May 13 2025
Baird
Locked
Locked
Locked Apr 28 2025
Morgan Stanley
Locked
Locked
Locked Mar 07 2025
JP Morgan
Locked
Locked
Locked Mar 05 2025
RBC Capital
Locked
Locked
Locked Mar 04 2025
HC Wainwright & Co.
Locked
Locked
Locked Mar 04 2025
Analyst Rating Date
Locked
RBC Capital:
Locked
Locked
May 19 2025
Locked
RBC Capital:
Locked
Locked
May 13 2025
Locked
Baird:
Locked
Locked
Apr 28 2025
Locked
Morgan Stanley:
Locked
Locked
Mar 07 2025
Locked
JP Morgan:
Locked
Locked
Mar 05 2025
Locked
RBC Capital:
Locked
Locked
Mar 04 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Mar 04 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today